$11.47
0.44% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US03152W1099
Symbol
FOLD
Sector
Industry

Amicus Therapeutics, Inc. Target price 2024 - Analyst rating & recommendation

Amicus Therapeutics, Inc. Classifications & Recommendation:

Buy
85%
Hold
15%

Amicus Therapeutics, Inc. Price Target

Target Price $17.33
Price $11.47
Potential
Number of Estimates 12
12 Analysts have issued a price target Amicus Therapeutics, Inc. 2025 . The average Amicus Therapeutics, Inc. target price is $17.33. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 11 Analysts recommend Amicus Therapeutics, Inc. to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Amicus Therapeutics, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Amicus Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 399.36 517.10
21.30% 29.48%
EBITDA Margin -16.43% 9.97%
72.83% 160.68%
Net Margin -37.86% -10.59%
48.73% 72.03%

13 Analysts have issued a sales forecast Amicus Therapeutics, Inc. 2024 . The average Amicus Therapeutics, Inc. sales estimate is

$517m
Unlock
. This is
13.48% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$523m 14.85%
Unlock
, the lowest is
$512m 12.38%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $399m 21.30%
2024
$517m 29.48%
Unlock
2025
$641m 23.89%
Unlock
2026
$817m 27.61%
Unlock
2027
$986m 20.60%
Unlock
2028
$1.2b 19.28%
Unlock

5 Analysts have issued an Amicus Therapeutics, Inc. EBITDA forecast 2024. The average Amicus Therapeutics, Inc. EBITDA estimate is

$51.5m
Unlock
. This is
409.02% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$113m 775.55%
Unlock
, the lowest is
$-5.3m 68.36%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-65.6m 67.04%
2024
$51.5m 178.55%
Unlock
2025
$145m 181.40%
Unlock
2026
$299m 106.23%
Unlock

EBITDA Margin

2023 -16.43% 72.83%
2024
9.97% 160.68%
Unlock
2025
22.64% 127.08%
Unlock
2026
36.59% 61.62%
Unlock

10 Amicus Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Amicus Therapeutics, Inc. net profit estimate is

$-54.8m
Unlock
. This is
53.80% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-29.6m 75.00%
Unlock
, the lowest is
$-88.9m 25.00%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-151m 37.80%
2024
$-54.8m 63.76%
Unlock
2025
$52.9m 196.53%
Unlock
2026
$176m 232.66%
Unlock
2027
$301m 71.32%
Unlock
2028
$433m 43.61%
Unlock

Net Margin

2023 -37.86% 48.73%
2024
-10.59% 72.03%
Unlock
2025
8.25% 177.90%
Unlock
2026
21.52% 160.85%
Unlock
2027
30.57% 42.05%
Unlock
2028
36.80% 20.38%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.51 -0.18
37.80% 64.71%
P/E negative
EV/Sales 6.93

10 Analysts have issued a Amicus Therapeutics, Inc. forecast for earnings per share. The average Amicus Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.18
Unlock
. This is
55.00% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.10 75.00%
Unlock
, the lowest is
$-0.30 25.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.51 37.80%
2024
$-0.18 64.71%
Unlock
2025
$0.18 200.00%
Unlock
2026
$0.59 227.78%
Unlock
2027
$1.02 72.88%
Unlock
2028
$1.46 43.14%
Unlock

P/E ratio

Current -28.70 72.37%
2024
-62.07 116.27%
Unlock
2025
64.30 203.59%
Unlock
2026
19.33 69.94%
Unlock
2027
11.28 41.65%
Unlock
2028
7.86 30.32%
Unlock

Based on analysts' sales estimates for 2024, the Amicus Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 7.87 15.38%
2024
6.93 11.88%
Unlock
2025
5.60 19.28%
Unlock
2026
4.39 21.63%
Unlock
2027
3.64 17.08%
Unlock
2028
3.05 16.16%
Unlock

P/S ratio

Current 7.47 14.89%
2024
6.58 11.88%
Unlock
2025
5.31 19.28%
Unlock
2026
4.16 21.63%
Unlock
2027
3.45 17.08%
Unlock
2028
2.89 16.16%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today